Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1

This study has been terminated.
(Unable to recruit adequate number of subjects)
Sponsor:
Collaborators:
VA Boston Healthcare System
Information provided by (Responsible Party):
Lawrence H. Price, Butler Hospital
ClinicalTrials.gov Identifier:
NCT00000309
First received: September 20, 1999
Last updated: April 15, 2013
Last verified: April 2013
  Purpose

The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Risperidone
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Serotonin/Dopamine Antagonism of Cocaine Effect

Resource links provided by NLM:


Further study details as provided by Butler Hospital:

Primary Outcome Measures:
  • Analog mood scales
  • POMS
  • EPS sx

Estimated Enrollment: 0
Study Start Date: August 1994
Primary Completion Date: January 2000 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000309

Locations
United States, Rhode Island
Brown University School of Medicine
Providence, Rhode Island, United States, 2906
Sponsors and Collaborators
Butler Hospital
VA Boston Healthcare System
Investigators
Principal Investigator: Lawrence Price, M.D. Brown University
  More Information

No publications provided

Responsible Party: Lawrence H. Price, Professor of Psychiatry and Human Behavior, Butler Hospital
ClinicalTrials.gov Identifier: NCT00000309     History of Changes
Other Study ID Numbers: NIDA-09330-1, R01DA009330, R01-09330-1
Study First Received: September 20, 1999
Last Updated: April 15, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Dopamine
Risperidone
Serotonin
Cardiotonic Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Serotonin Receptor Agonists
Serotonin Agents
Serotonin Antagonists
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Central Nervous System Agents
Psychotropic Drugs
Dopamine Antagonists

ClinicalTrials.gov processed this record on July 23, 2014